Trial · NCT02122211
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in sperm motility from baseline | On day zero, day 10, day 30, day 50 and at the end of the 75 day treatment period | Assessed using Computer-Aided Sperm Analysis methodology |
| Primary | Change in sperm count from baseline | On day zero, day 10, day 30, day 50 and at the end of the 75 day treatment period | |
| Primary | Change in sperm mitochondrial function from baseline | On day zero, day 10, day 30, day 50 and at the end of the 75 day treatment period | Using Seahorse biochemical function assessment |
| Primary | Change in sperm ultrastructure from baseline | On day zero, day 10, day 30, day 50 and at the end of the 75 day treatment period | Using light and transmission electron microscopy |
| Primary | Change in sperm choline dehydrogenase concentration from baseline | On day zero, day 10, day 30, day 50 and at the end of the 75 day treatment period | Assessed by Western Blot analysis |
| Primary | Change in sperm betaine concentration from baseline | On day zero, day 10, day 30, day 50 and at the end of the 75 day treatment period | |
| Secondary | Betaine intake | At screening and every 21 days during the study | Assessed using 3-day food records |
| Secondary | Change in complete blood count from baseline | At 0, 10, 30, 50, and 75 days on treatment | |
| Secondary | Change in uric acid concentration from baseline | At 0, 10, 30, 50, and 75 days on treatment | |
| Secondary | Change in alkaline phosphatase concentration from baseline | At 0, 10, 30, 50, and 75 days on treatment | |
| Secondary | Change in aspartate transaminase concentration from baseline | At 0,10, 30, 50, and 75 days on treatment | |
| Secondary | Change in lactic dehydrogenase concentration from baseline | At 0, 10, 30, 50, and 75 days on treatment | |
| Secondary | Change in bilirubin concentration from baseline | At 0, 10, 30, 50, and 75 days on treatment | |
| Secondary | Change in blood urea nitrogen concentration from baseline | At 0, 10, 30, 50, and 75 days on treatment | |
| Secondary | Change in creatinine concentration from baseline | At 0, 10, 30, 50, and 75 days on treatment | |
| Secondary | Change in urinalysis parameters from baseline | At 0, 10, 30, 50, and 75 days on treatment |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02122211/registered